HYTN Innovations Inc (TSE:HYTN) has released an update.
HYTN Innovations Inc. has been awarded a Drug Establishment License by Health Canada, permitting the company to produce and export pharmaceuticals containing cannabis and psilocybin into regulated global markets. This license solidifies HYTN’s position as a rare entity with the ability to manufacture non-sterile pharmaceuticals to Good Manufacturing Practice (GMP) standards, paving the way for expansion into international markets like the UK, Germany, and Australia. HYTN’s CEO and COO highlight the license as a major milestone, showcasing their high manufacturing standards and opening new opportunities in the medical sector.
For further insights into TSE:HYTN stock, check out TipRanks’ Stock Analysis page.
